TRANSMEDICS GROUP INC (TMDX) Fundamental Analysis & Valuation

NASDAQ:TMDX • US89377M1099

Current stock price

110.93 USD
-2.28 (-2.01%)
At close:
110.45 USD
-0.48 (-0.43%)
After Hours:

This TMDX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. TMDX Profitability Analysis

1.1 Basic Checks

  • TMDX had positive earnings in the past year.
  • In the past year TMDX had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: TMDX reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: TMDX reported negative operating cash flow in multiple years.
TMDX Yearly Net Income VS EBIT VS OCF VS FCFTMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 17.81%, TMDX belongs to the top of the industry, outperforming 96.79% of the companies in the same industry.
  • TMDX's Return On Equity of 40.22% is amongst the best of the industry. TMDX outperforms 98.40% of its industry peers.
  • TMDX has a better Return On Invested Capital (8.76%) than 86.63% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for TMDX is below the industry average of 9.12%.
  • The last Return On Invested Capital (8.76%) for TMDX is above the 3 year average (4.27%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 17.81%
ROE 40.22%
ROIC 8.76%
ROA(3y)6.23%
ROA(5y)-5.44%
ROE(3y)12.5%
ROE(5y)-9.39%
ROIC(3y)4.27%
ROIC(5y)N/A
TMDX Yearly ROA, ROE, ROICTMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 200 300 400

1.3 Margins

  • Looking at the Profit Margin, with a value of 31.43%, TMDX belongs to the top of the industry, outperforming 98.93% of the companies in the same industry.
  • TMDX's Operating Margin of 17.93% is amongst the best of the industry. TMDX outperforms 89.30% of its industry peers.
  • TMDX's Gross Margin of 59.92% is fine compared to the rest of the industry. TMDX outperforms 61.50% of its industry peers.
  • In the last couple of years the Gross Margin of TMDX has declined.
Industry RankSector Rank
OM 17.93%
PM (TTM) 31.43%
GM 59.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.98%
GM growth 5Y-1.58%
TMDX Yearly Profit, Operating, Gross MarginsTMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. TMDX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TMDX is creating some value.
  • TMDX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, TMDX has more shares outstanding
  • TMDX has a better debt/assets ratio than last year.
TMDX Yearly Shares OutstandingTMDX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
TMDX Yearly Total Debt VS Total AssetsTMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 5.10 indicates that TMDX is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 5.10, TMDX is in the better half of the industry, outperforming 77.54% of the companies in the same industry.
  • The Debt to FCF ratio of TMDX is 3.84, which is a good value as it means it would take TMDX, 3.84 years of fcf income to pay off all of its debts.
  • TMDX has a better Debt to FCF ratio (3.84) than 78.61% of its industry peers.
  • TMDX has a Debt/Equity ratio of 1.06. This is a high value indicating a heavy dependency on external financing.
  • TMDX's Debt to Equity ratio of 1.06 is on the low side compared to the rest of the industry. TMDX is outperformed by 78.07% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF 3.84
Altman-Z 5.1
ROIC/WACC1.08
WACC8.12%
TMDX Yearly LT Debt VS Equity VS FCFTMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 7.14 indicates that TMDX has no problem at all paying its short term obligations.
  • TMDX has a Current ratio of 7.14. This is amongst the best in the industry. TMDX outperforms 86.10% of its industry peers.
  • TMDX has a Quick Ratio of 6.59. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
  • TMDX has a Quick ratio of 6.59. This is amongst the best in the industry. TMDX outperforms 86.10% of its industry peers.
Industry RankSector Rank
Current Ratio 7.14
Quick Ratio 6.59
TMDX Yearly Current Assets VS Current LiabilitesTMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. TMDX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 178.22% over the past year.
  • Looking at the last year, TMDX shows a very strong growth in Revenue. The Revenue has grown by 37.13%.
  • TMDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 88.21% yearly.
EPS 1Y (TTM)178.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%178.95%
Revenue 1Y (TTM)37.13%
Revenue growth 3Y86.42%
Revenue growth 5Y88.21%
Sales Q2Q%32.18%

3.2 Future

  • TMDX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.03% yearly.
  • The Revenue is expected to grow by 17.79% on average over the next years. This is quite good.
EPS Next Y-11.67%
EPS Next 2Y14.76%
EPS Next 3Y19.73%
EPS Next 5Y12.03%
Revenue Next Year22.82%
Revenue Next 2Y20.77%
Revenue Next 3Y18.99%
Revenue Next 5Y17.79%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TMDX Yearly Revenue VS EstimatesTMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
TMDX Yearly EPS VS EstimatesTMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 4 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

4

4. TMDX Valuation Analysis

4.1 Price/Earnings Ratio

  • TMDX is valuated quite expensively with a Price/Earnings ratio of 39.48.
  • Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than 68.98% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of TMDX to the average of the S&P500 Index (27.42), we can say TMDX is valued slightly more expensively.
  • A Price/Forward Earnings ratio of 44.69 indicates a quite expensive valuation of TMDX.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 68.45% of the companies listed in the same industry.
  • TMDX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.24.
Industry RankSector Rank
PE 39.48
Fwd PE 44.69
TMDX Price Earnings VS Forward Price EarningsTMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 70.05% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 78.07% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 28.68
EV/EBITDA 28.98
TMDX Per share dataTMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • TMDX has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as TMDX's earnings are expected to grow with 19.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.76%
EPS Next 3Y19.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TMDX Dividend Analysis

5.1 Amount

  • No dividends for TMDX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TMDX Fundamentals: All Metrics, Ratios and Statistics

TRANSMEDICS GROUP INC

NASDAQ:TMDX (4/24/2026, 8:11:16 PM)

After market: 110.45 -0.48 (-0.43%)

110.93

-2.28 (-2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-24
Earnings (Next)05-05
Inst Owners111.22%
Inst Owner Change0.03%
Ins Owners2.98%
Ins Owner Change1.41%
Market Cap3.83B
Revenue(TTM)605.49M
Net Income(TTM)190.29M
Analysts83
Price Target162.18 (46.2%)
Short Float %24.13%
Short Ratio8.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.66%
Min EPS beat(2)32.92%
Max EPS beat(2)84.39%
EPS beat(4)4
Avg EPS beat(4)96.18%
Min EPS beat(4)32.92%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)170.32%
EPS beat(12)10
Avg EPS beat(12)118.73%
EPS beat(16)13
Avg EPS beat(16)92.69%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)1.22%
Revenue beat(4)3
Avg Revenue beat(4)4.11%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)5.48%
Revenue beat(12)10
Avg Revenue beat(12)10.09%
Revenue beat(16)14
Avg Revenue beat(16)16.58%
PT rev (1m)8.9%
PT rev (3m)8.97%
EPS NQ rev (1m)-0.96%
EPS NQ rev (3m)-11.62%
EPS NY rev (1m)-5.06%
EPS NY rev (3m)-15.99%
Revenue NQ rev (1m)-1.06%
Revenue NQ rev (3m)0.62%
Revenue NY rev (1m)-0.21%
Revenue NY rev (3m)1.88%
Valuation
Industry RankSector Rank
PE 39.48
Fwd PE 44.69
P/S 6.33
P/FCF 28.68
P/OCF 19.87
P/B 8.1
P/tB 8.34
EV/EBITDA 28.98
EPS(TTM)2.81
EY2.53%
EPS(NY)2.48
Fwd EY2.24%
FCF(TTM)3.87
FCFY3.49%
OCF(TTM)5.58
OCFY5.03%
SpS17.53
BVpS13.7
TBVpS13.31
PEG (NY)N/A
PEG (5Y)N/A
Graham Number29.4279 (-73.47%)
Profitability
Industry RankSector Rank
ROA 17.81%
ROE 40.22%
ROCE 11.09%
ROIC 8.76%
ROICexc 17.48%
ROICexgc 17.98%
OM 17.93%
PM (TTM) 31.43%
GM 59.92%
FCFM 22.06%
ROA(3y)6.23%
ROA(5y)-5.44%
ROE(3y)12.5%
ROE(5y)-9.39%
ROIC(3y)4.27%
ROIC(5y)N/A
ROICexc(3y)8.3%
ROICexc(5y)N/A
ROICexgc(3y)8.55%
ROICexgc(5y)N/A
ROCE(3y)5.4%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.98%
GM growth 5Y-1.58%
F-Score7
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF 3.84
Debt/EBITDA 3.7
Cap/Depr 217.96%
Cap/Sales 9.79%
Interest Coverage 10.15
Cash Conversion 142.04%
Profit Quality 70.2%
Current Ratio 7.14
Quick Ratio 6.59
Altman-Z 5.1
F-Score7
WACC8.12%
ROIC/WACC1.08
Cap/Depr(3y)910.54%
Cap/Depr(5y)653.45%
Cap/Sales(3y)34%
Cap/Sales(5y)25.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)178.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%178.95%
EPS Next Y-11.67%
EPS Next 2Y14.76%
EPS Next 3Y19.73%
EPS Next 5Y12.03%
Revenue 1Y (TTM)37.13%
Revenue growth 3Y86.42%
Revenue growth 5Y88.21%
Sales Q2Q%32.18%
Revenue Next Year22.82%
Revenue Next 2Y20.77%
Revenue Next 3Y18.99%
Revenue Next 5Y17.79%
EBIT growth 1Y189.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60%
EBIT Next 3Y45.75%
EBIT Next 5Y46.88%
FCF growth 1Y265.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y295.14%
OCF growth 3YN/A
OCF growth 5YN/A

TRANSMEDICS GROUP INC / TMDX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?

ChartMill assigns a fundamental rating of 6 / 10 to TMDX.


Can you provide the valuation status for TRANSMEDICS GROUP INC?

ChartMill assigns a valuation rating of 4 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.


Can you provide the profitability details for TRANSMEDICS GROUP INC?

TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 6 / 10.


What are the PE and PB ratios of TRANSMEDICS GROUP INC (TMDX) stock?

The Price/Earnings (PE) ratio for TRANSMEDICS GROUP INC (TMDX) is 39.48 and the Price/Book (PB) ratio is 8.1.


Can you provide the expected EPS growth for TMDX stock?

The Earnings per Share (EPS) of TRANSMEDICS GROUP INC (TMDX) is expected to decline by -11.67% in the next year.